Study of R-ACVBP [rituximab + doxorubicin + cyclophosphamide + vindesine + bleomycin + cortisone] regimen supported by pegfilgrastim in previously untreated patients aged from 18 to 60 years with high-risk diffuse large B-cell lymphoma (age-adjusted Ipi greater than or equal to 2).

Trial Profile

Study of R-ACVBP [rituximab + doxorubicin + cyclophosphamide + vindesine + bleomycin + cortisone] regimen supported by pegfilgrastim in previously untreated patients aged from 18 to 60 years with high-risk diffuse large B-cell lymphoma (age-adjusted Ipi greater than or equal to 2).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Sep 2006

At a glance

  • Drugs Bleomycin; Cortisone; Cyclophosphamide; Doxorubicin; Pegfilgrastim; Rituximab; Vindesine
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top